极早产儿动脉导管未闭选择性早期药物治疗的试点随机对照试验(SMART-PDA)
本研究为多中心随机对照试验,旨在评估对极早产儿进行早期综合血流动力学筛查并选择性治疗高流量动脉导管未闭的可行性与临床效果。结果显示,该策略方案偏离率低(1.9%),肺出血显著减少,且在患者重要结局的Win比率上优于对照组的概率为85%。
要点
- 早期综合血流动力学筛查并选择性治疗高流量PDA在极早产儿中可行,方案偏离率仅1.9%。
- 该策略使肺出血显著减少,并在患者重要结局上呈现85%概率优于常规处理。
- 仍需更大规模随机对照试验验证其对生存率等硬结局的改善作用。
核心结论
- 在极早产儿中,基于早期综合血流动力学筛查的选择性PDA药物治疗策略是可行的,且可能提高患者重要结局改善的概率。
研究设计与样本
- 多中心随机对照试验(SMART-PDA),纳入符合条件婴儿的63%,方案偏离率1.9%。
主要发现
- 肺出血显著减少。
- 早期筛查与选择性治疗策略在患者重要结局的Win比率上优于对照组的概率为85%。
关键数值与推荐
- 纳入符合条件婴儿的63%,方案偏离率1.9%。
- 患者重要结局Win比率优于对照组的概率为85%。
临床怎么用
- 对于极早产儿,可考虑实施早期综合血流动力学筛查以识别高流量PDA并选择性进行药物治疗。
局限性
- 作为试点研究,结论需更大规模随机对照试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
WHAT IS ALREADY KNOWN ON THIS TOPIC Large pragmatic randomised controlled trials (RCTs) have not demonstrated improvement in patient-important outcomes with medical treatment of the patent ductus arteriosus (PDA). Uncertainty exists on whether an early comprehensive haemodynamic screening and selective treatment of high-volume PDA shunts in the smallest infants is feasible and if it improves clinical outcomes. WHAT THIS STUDY ADDS This multicentre randomised clinical trial enrolled 63% of eligible infants with 1.9% protocol deviation. Pulmonary haemorrhage was substantially reduced. The early screening and selective treatment approach had an 85% probability of a better Win ratio with regards to patient-important outcomes compared with control. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY An RCT of selective early PDA treatment based on a comprehensive haemodynamic screening in the smallest infants is feasible and such an approach may provide a better probability of survival...
引用
- ADC Fetal and Neonatal:Selective early medical treatment of the patent ductus arteriosus in extremely low gestational age infants: a pilot randomised controlled trial (SMART-PDA)
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。